18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions (FDOPA)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Brain Tumor

Treatments: Diagnostic Test: FDOPA-TEP

Study type: Observational

Funder types: Other

Identifiers

NCT04306484

LOCAL/2020/DR-01

Details and patient eligibility

About

Background: 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) can identify well low and high grade brain tumors. However, increased FDOPA uptake has been reported in non-tumoral brain lesions. The aim was to analyse FDOPA-PET in patients with non-tumoral brain lesions and to compare them with patients with (low and high grade) brain tumors.

Methods: retrospective analyse. Patients consecutively recruited with suspected primary brain tumor (based on clinical and MRI findings) referred for FDOPA-PET at Nimes university Hospital between June 2015 and June 2019. FDOPA-PET parameters (maximum and mean lesion standardized uptake values [SUV] and ratios comparing lesion with different background uptake SUV) and thresholds were analysed in search for those offering optimal discrimination between non-tumoral and tumoral lesions.

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• presence of defined tumor (histology was required) or non-tumor (diagnosed by histological or other analyses) diagnosis,
• clinical and MRI follow-up of >24 months,
• FDOPA-PET scan <2 months before surgery or stereotactic biopsy (when performed)

Trial design

74 participants in 2 patient groups

patients with tumoral brain lesion

Description:

The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.

Treatment:

Diagnostic Test: FDOPA-TEP

patients with non-tumoral brain lesion

Description:

The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).

Treatment:

Diagnostic Test: FDOPA-TEP